Sei Investments Co. Sells 27,582 Shares of Sanofi $SNY

Sei Investments Co. reduced its stake in shares of Sanofi (NASDAQ:SNY) by 4.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 588,729 shares of the company’s stock after selling 27,582 shares during the period. Sei Investments Co.’s holdings in Sanofi were worth $28,366,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Advisory Services Network LLC grew its holdings in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares during the last quarter. Savant Capital LLC lifted its stake in shares of Sanofi by 2.7% in the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after buying an additional 225 shares during the last quarter. Wesbanco Bank Inc. boosted its holdings in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after buying an additional 230 shares during the period. IFG Advisory LLC grew its stake in Sanofi by 2.7% in the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after buying an additional 244 shares during the last quarter. Finally, Cohen Investment Advisors LLC raised its holdings in Sanofi by 2.9% in the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after acquiring an additional 263 shares during the period. 14.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. Morgan Stanley set a $49.00 price target on shares of Sanofi in a report on Wednesday, July 8th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Wall Street Zen cut Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Monday, April 20th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Performance

NASDAQ SNY opened at $44.00 on Tuesday. The company’s fifty day moving average is $43.45 and its two-hundred day moving average is $45.31. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The firm has a market capitalization of $106.67 billion, a price-to-earnings ratio of 12.29, a P/E/G ratio of 1.10 and a beta of 0.34.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.